The anticipated growth in the market is primarily driven by the rising incidence of chronic diseases and the increasing significance of nano proteomics. Furthermore, advancements in technology and increased research and development (R&D) investments are expected to create additional opportunities for the proteomics sector. Conversely, the high costs associated with proteomics instruments and the shortage of skilled professionals present challenges to market expansion.
Proteomics, which involves the comprehensive analysis of proteins, plays a crucial role in drug development, therapeutic interventions, prognosis, and disease characterization. Technologies in proteomics facilitate the detection and treatment of both infectious and non-infectious diseases. Current methodologies in proteomics are being enhanced for reliability, biocompatibility, specificity, and reproducibility through the integration of nanotechnology. The application of nanomaterials significantly improves traditional proteomic techniques, allowing for better protein manipulation. In the pharmaceutical industry, proteomics is essential for studying drug effects and toxicity mechanisms, as well as for identifying and validating biomarkers.
In 2022, North America held a substantial share of the global proteomics market. This region's market is divided into the United States, Canada, and Mexico. Key factors propelling market growth in North America include increased investments in structure-based drug design, a demand for high-quality research tools that ensure data reproducibility, and a surge in omics research. There is a growing focus on developing personalized treatments, and collaborations among major companies in the region are further driving market growth. For instance, Thermo Fisher Scientific Inc. and Symphogen have partnered to create validated platform processes aimed at optimizing the characterization and quality monitoring of complex therapeutic proteins. Additionally, proteomics research is thriving in the United States.
Technological advancements and increased R&D spending are expected to provide future opportunities in the proteomics market. Companies in this sector are concentrating on innovative methods and devices for disease diagnosis. For example, Agilent Technologies, Inc. has recognized the benefits of technology out-licensing strategies to enhance product development for protein analysis. The advent of proteomics technology has enabled the absolute quantification of protein-based diagnostics. The market is underpinned by key proteomic services and technologies, including microarray, X-ray crystallography, spectroscopic techniques, chromatography, electrophoresis, and surface plasmon resonance systems.
The surge in R&D investments in proteomics is significantly contributing to market growth. The US National Institutes of Health (NIH) allocated US$ 37 billion for biomedical research, which will support investigations into the fundamental mechanisms of disease, the identification of disease biomarkers, and the discovery of genes or proteins responsible for diseases. Additionally, the Novo Nordisk Foundation awarded the University of Copenhagen a grant of up to US$ 1.5 million to establish a mass spectrometry facility, a vital step for advancing protein research. The market experienced rapid growth following the COVID-19 pandemic.
Key industry players are essential in enhancing access to quality healthcare and medications in developing nations, which in turn boosts economic opportunities. They are also focused on job creation, significant investments, influencing public policy, and providing training. The pharmaceutical sector plays a pivotal role in generating economic opportunities in these regions. Recently, pharmaceutical companies have reported impressive financial outcomes. For instance, Thermo Fisher Scientific, Inc. achieved record profits last year, with expectations for even stronger future performance. The market is poised for continued growth as numerous biopharmaceutical companies emerge as key players, and various R&D initiatives are undertaken, thereby creating further opportunities for the global market.
Insights Based on Product & Service
The proteomics market is categorized by product and service into instrumentation technologies, reagents & consumables, and software & services. In 2022, the reagents & consumables segment dominated the market and is projected to exhibit the highest CAGR of 14.1% from 2022 to 2030.
Reagents, kits, consumables, and strips are increasingly utilized for the examination of various biological materials in research universities, institutions, and other settings. Government initiatives supporting proteomics and genomics research are driving activity in disease diagnostics. Technological advancements in sophisticated instruments, such as 3D electrophoresis protein analyzers, which enhance the speed, efficiency, and productivity of biological research, are also fueling demand for reagents and consumables. These factors are contributing to the growth of the proteomics market in this segment.
Insights Based on Application
The market is segmented by application into clinical diagnostics, drug discovery & development, and others. The clinical diagnostics segment held the largest share of the proteomics market in 2022, while the drug discovery & development segment is anticipated to achieve the highest CAGR of 14.4% during the forecast period from 2022 to 2030.
Insights Based on End User
The market is divided by end user into pharmaceutical & biotechnology companies, research & clinical laboratories, hospitals, and others. The pharmaceutical & biotechnology companies segment accounted for the largest share of the proteomics market in 2022, whereas the research & clinical laboratories segment is expected to register the highest CAGR of 14.5% from 2022 to 2030.
Leading companies are adopting strategies such as expansion, partnerships, new product launches, and customer base acquisitions to capitalize on existing business opportunities.
The proteomics market report is prepared using primary and secondary sources, including the US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and the Global Burden of Disease Study.